Document Detail


CD20 antigen imaging with <formula>^{124}</formula>I-rituximab PET/CT in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  21558621     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Introduction: Visualization of the CD20-antigen expression could provide a tool to localize sites of inflammation and could be of additive value in the diagnosis, and subsequently, in the treatment follow-up of patients with rheumatoid arthritis. In this study, an anti-CD20 monoclonal antibody, rituximab (Mabthera®), was radiolabeled with <formula>^{124}</formula>Iodine. We report the first results of <formula>^{124}</formula>I-rituximab PET/CT in patients with rheumatoid arthritis. Methods: Eligible patients received 50 MBq <formula>^{124}</formula>I-rituximab. Wholebody PET/CT imaging was performed at 10 min, 24 h, 48 h and 72-96 h post injection. Images were evaluated primarily on a visual basis and were correlated with disease activity as determined by physical examination and clinical measures. Results: Joints with visually detectable targeting of <formula>^{124}</formula>I-rituximab were observed in 4 out of 5 evaluable patients. Only the images at 24 h and later showed accumulation in joints, indicating that the visualized signal represented active targeting of rituximab to the CD20 antigen. Several images showed CD20 positive B-cell infiltration in joints which were clinically normal, while a few clinically diagnosed arthritis localizations were not visualized. This discrepancy suggests that infiltration of CD20 positive B-cells in synovium is a phenomenon that is at least partially independent of clinical inflammation. The level of uptake in joints was generally low, representing less than 0.5% of the injected dose. Conclusion: We have shown the feasibility of CD20 antigen imaging using <formula>^{124}</formula>I-rituximab in patients with rheumatoid arthritis. Further research is needed to elucidate the clinical significance of demonstrated B-cell infiltration in rheumatic joints.
Authors:
L Tran; A D R Huitema; M H van Rijswijk; H J Dinant; J W Baars; J H Beijnen; W V Vogel
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Human antibodies     Volume:  20     ISSN:  1875-869X     ISO Abbreviation:  Hum Antibodies     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-05-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9711270     Medline TA:  Hum Antibodies     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  29-35     Citation Subset:  IM    
Affiliation:
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute / Slotervaart Hospital, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Generation of novel recombinant antibodies against nitrotyrosine by antibody phage display.
Next Document:  The pharmacokinetics of <formula>^{131}</formula>I-rituximab in a patient with CD20 positive Non-Hod...